Johnson & Johnson vs Medtronic

8-K Financial Filing Analysis for Johnson & Johnson (2026-08-04)

On August 4, 2026, Johnson & Johnson filed a Form 8-K announcing the retirement of Jennifer Taubert from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026. This represents a significant leadership transition for Johnson & Johnson's core pharmaceutical and innovative medicine division, which accounts for a substantial portion of the company's global revenue and R&D pipeline.

• Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine, effective September 1, 2026.
• Taubert will simultaneously step down from her role as a member of Johnson & Johnson's Executive Committee.
• The announcement was formalized via Form 8-K under Item 5.02 on August 4, 2026.

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.

A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma

Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.

XRlabs Raises €7.48M for AI Surgical Intelligence

London-based XRlabs, a Surgical Intelligence company founded by neurosurgeon Dr. Ali Haddad, has raised €7.48 million ($8.4 million) in Seed funding. The round was led by Playground Global (Palo Alto), with participation from London-based HealthTech investor Eka Ventures. The company develops modular, device-agnostic software that uses computer vision and deep learning to transform live surgical video, navigation telemetry, and pre-operative imaging into a real-time, anatomy-aware view. Its platform has been deployed in over 100 surgical cases across three continents. The funding will support engineering and clinical team expansion, regulatory advancement in the UK, EU, and US, and the extension of clinical evidence. XRlabs also announced Omar Ishrak, former CEO of Medtronic, as Chair of its Board. The company has been awarded compute allocation on the UK AI Research Resource (AIRR).

• XRlabs raised €7.48 million ($8.4 million) in Seed funding led by Playground Global with participation from Eka Ventures.
• Omar Ishrak, former CEO of Medtronic, joined as Chair of XRlabs' Board of Directors.
• The company's platform has been deployed in over 100 surgical cases on three continents.

8-K Financial Filing Analysis for Medtronic (2026-09-01)

On September 1, 2026, Medtronic plc filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its financial results for the first quarter of fiscal year 2027. The details of the quarterly performance were furnished via press release in Exhibit 99.1, signed by Executive Vice President and Chief Financial Officer Thierry Piéton.

• Medtronic plc furnished its Q1 FY2027 financial results via Form 8-K on September 1, 2026.
• The earnings announcement is furnished under Item 2.02 with details provided in Exhibit 99.1.
• The filing was formally authorized and signed by Executive Vice President and CFO Thierry Piéton.

Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc.